7 Facts About CJC-1295 No DAC and Ipamorelin Research
Last Updated: October 29, 2026
Quick Summary
CJC-1295 no DAC and Ipamorelin is a two-peptide research combination pairing a short-acting growth hormone-releasing hormone analog with a selective ghrelin receptor agonist. Researchers study it because the two components act on separate receptors, GHRH and GHS-R1a, that converge on the same downstream release pathway.
- CJC-1295 without DAC is a 29-amino acid Modified GRF 1-29 analog with no albumin-binding shield.
- Ipamorelin is a five-amino acid pentapeptide that binds the ghrelin receptor GHS-R1a.
- The no-DAC variant’s short half-life makes it suited to pulsatile release models, not sustained exposure.
- Human controlled trial data specific to this combination is sparse, with most support at evidence tiers three and four.
- Verify a COA with a matching batch number and full HPLC chromatogram before running any assay.
Table of Contents
- What CJC-1295 No DAC and Ipamorelin Are in Laboratory Research
- CJC-1295 No DAC Mechanism of Action at the Receptor Level
- CJC-1295 No DAC vs DAC: Half-Life, Clearance, and Pulse Patterns
- CJC-1295 and Ipamorelin Research: What the Combination Is Studied For
- CJC-1295 Peptide Purity Testing and Independent Verification
- Evidence Grading, Regulatory Status, and Risk Groups in the Literature
- Selecting Research-Grade CJC-1295 No DAC and Ipamorelin
- Frequently Asked Questions
What CJC-1295 No DAC and Ipamorelin Are in Laboratory Research
CJC-1295 no DAC and Ipamorelin is a two-peptide research combination that pairs a growth hormone-releasing hormone analog with a selective ghrelin receptor agonist. At The Peptides King, we supply this blend as a laboratory reference material for receptor-signaling studies, not as a therapeutic product.
The first component, CJC-1295 without DAC, is a 29-amino acid synthetic analog of growth hormone-releasing hormone, often written as Modified GRF 1-29. It carries four amino acid substitutions that resist enzymatic breakdown while leaving the Drug Affinity Complex off the molecule entirely.
The second component, Ipamorelin, is a five-amino acid pentapeptide that binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Researchers pair the two because they act on complementary receptor pathways.
CJC-1295 No DAC Mechanism of Action at the Receptor Level
CJC-1295 no DAC mechanism of action begins at the GHRH receptor on pituitary somatotroph cells. The Modified GRF 1-29 sequence binds that receptor and triggers adenylate cyclase signaling, which raises intracellular cAMP and drives downstream release signaling in the cell model.
Ipamorelin takes a separate route. It binds the ghrelin receptor, GHS-R1a, and initiates G-protein activation that produces pulsatile signaling patterns without engaging cortisol or prolactin pathways, according to the compound’s published research profile.
The practical value for a lab is the separation. Because the two peptides hit different receptors, a study can observe co-activation of GHRH and ghrelin pathways in the same assay. What most guides miss is that this dual activation is a signaling question, not a dosing question. The readout is receptor affinity and downstream transcription markers, not an outcome claim.
CJC-1295 No DAC vs DAC: Half-Life, Clearance, and Pulse Patterns
CJC-1295 no DAC vs DAC comes down to one structural difference and one big behavioral consequence. The DAC version carries a maleimide group that binds covalently to albumin, shielding the peptide from DPP-4 cleavage and renal clearance. The no-DAC version has no such shield.
| Feature | CJC-1295 No DAC | CJC-1295 DAC |
|---|---|---|
| Sequence | Modified GRF 1-29 | Tetrasubstituted GRF 1-29 plus DAC |
| Albumin binding | None | Covalent maleimide linkage |
| Half-life profile | Short-acting | Extended |
| Clearance | Rapid enzymatic and renal | Slowed by bioconjugation |
| Release pattern studied | Pulsatile | Continuous, non-pulsatile |
| Typical assay use | Pulse-pattern models | Sustained-exposure models |
That short half-life is the whole point of the no-DAC variant. A short-acting peptide lets researchers model natural growth hormone pulses in a controlled window. The DAC analog does the opposite: it produces continuous receptor interaction, which is useful for sustained-exposure work. If your protocol needs a pulsatile readout, the no-DAC form fits. If it needs a prolonged signal, the DAC form does. You can view the CJC-1295 DAC research vial for a direct side-by-side reference.
CJC-1295 and Ipamorelin Research: What the Combination Is Studied For
CJC-1295 and Ipamorelin research centers on growth hormone signaling, not on claimed outcomes. The pairing is studied because the two peptides act on separate receptors that converge on the same downstream release pathway, which makes the blend a useful model for asking how co-activation of GHRH and ghrelin signaling differs from activating either pathway alone.
The mechanistic rationale is straightforward. CJC-1295 without DAC binds the GHRH receptor on pituitary somatotroph cells and raises intracellular cAMP through adenylate cyclase. Ipamorelin binds GHS-R1a, the ghrelin receptor, and drives a separate G-protein cascade. In published cell and animal work, GHRH-receptor signaling and ghrelin-receptor signaling are described as complementary inputs to growth hormone release, and the combination is used to examine whether those inputs produce additive, synergistic, or simply parallel effects in a given model.
A second line of inquiry concerns pulse architecture. Because the no-DAC form is short-acting, researchers use it to model discrete release events, while Ipamorelin’s receptor engagement is studied for its effect on pulse amplitude and frequency in animal models. The combination therefore appears in work on pulsatility itself, not only on total release.
The literature describes several areas of interest: sleep-quality markers, body-composition parameters, recovery and strength measures, and growth hormone release dynamics. Note the wording. These are study endpoints, not established benefits. Human clinical evidence for the combination remains thin, and most of what circulates online is anecdotal reports rather than controlled trial data. We treat that gap as the most important thing a researcher should know, and the next section grades the evidence explicitly.
A useful way to frame the combination in a study design is as a two-receptor probe: one arm activates GHRH signaling, one arm activates ghrelin-receptor signaling, and the blend tests their interaction. Keep the readout tied to the assay, not to consumer claims.
For work focused on the Ipamorelin half of the pair, the standalone Ipamorelin 10mg vial lets you run a single-receptor control alongside the blend. Running the blend against each single-agent arm is the cleanest way to separate combination effects from single-pathway effects in the same assay batch.
CJC-1295 Peptide Purity Testing and Independent Verification
CJC-1295 peptide purity testing is where a supplier’s claims either hold up or fall apart. High-performance liquid chromatography separates the peptide from impurities and degradation fragments, and the resulting chromatogram shows a purity percentage. Mass spectrometry confirms the molecular weight matches the expected sequence.
A certificate of analysis is only as good as the lab behind it. Ask three questions: does the COA carry a batch number that matches your vial, does it include the actual chromatogram rather than a summary line, and is the testing lab independent of the supplier? For a deeper walkthrough of the method itself, read how HPLC testing verifies peptide purity.
A COA with no batch number and no chromatogram is a weak verification record, so check for both before the assay.
Evidence Grading, Regulatory Status, and Risk Groups in the Literature
Regulatory status is the fact most competitor pages skip. In the United States, CJC-1295 and Ipamorelin are not FDA-approved drug products. They are sold as research chemicals for laboratory use, and that label carries real obligations: the material is intended for controlled research, not for human consumption, and marketing language does not change its regulatory category. The FDA guidance on research-use-only products frames how these materials are distinguished from approved drugs. A research-use label is a statement about intended use, not a finding of safety or efficacy.
Evidence grading matters just as much, and it is where most guides stop short. Rank the sources you read:
- Peer-reviewed human trials with controlled designs
- Animal and in vitro studies
- Manufacturer literature and product pages
- Anecdotal reports from forums and social media
Most of what you will find for this combination sits at levels three and four. Human controlled trial data specific to the CJC-1295 no DAC plus Ipamorelin blend is sparse; much of the mechanistic support comes from animal and laboratory work on the individual peptides, and extrapolating from single-peptide animal data to a human combination protocol is a leap the literature does not license. When you read a claim, ask which tier it comes from and whether the study measured the combination or only one component.
Risk characterization follows the same logic. Drug interactions, contraindications, and risk groups are poorly characterized for this combination in humans, which is precisely why it belongs in a lab, not a self-administered protocol. A careful reading of the individual-peptide literature flags areas that warrant qualified medical review rather than generic side-effect lists: pre-existing endocrine conditions, pregnancy and lactation, pediatric use, and concurrent use of other growth-hormone-axis compounds.
Nothing in this section is dosing advice. Online protocols circulate widely, but a schedule posted on a forum is not validated medical guidance, and the absence of reported harm is not evidence of safety. Researchers should confirm institutional review, material documentation, and qualified oversight before any work involving human subjects.
Researchers working with the blend should also review peptide endotoxin testing requirements and confirm COA verification before any assay begins. Evidence grading and material verification are two halves of the same discipline: a well-designed study on an unverified batch produces uninterpretable results.
Selecting Research-Grade CJC-1295 No DAC and Ipamorelin
Selecting a supplier is a documentation exercise, not a price comparison. Run every candidate through the same checklist:
- COA includes a batch number matching the vial label
- Full HPLC chromatogram supplied, not a summary purity figure
- Mass spectrometry confirmation of molecular weight
- Endotoxin and heavy metals testing documented
- Testing performed by an independent laboratory
- Supplier states a replacement policy for out-of-spec batches
- Shipping timeline confirmed in writing
Our own standard at The Peptides King is HPLC-tested compounds with verified COAs and fast shipping. For labs ready to source the exact pair discussed here, the CJC-1295 no DAC and Ipamorelin blend is listed with its specifications, and the full research peptides catalog covers the single-agent controls and related reference materials that round out a well-designed assay panel.
Frequently Asked Questions
What does CJC-1295 no DAC with Ipamorelin do in research models?
In laboratory models, CJC-1295 no DAC (Modified GRF 1-29) acts on growth hormone-releasing hormone receptors, while Ipamorelin acts on the ghrelin receptor, GHS-R1a. Researchers study the pair because the two pathways are complementary and can be observed together in the same assay. The combination is described as producing pulsatile signaling rather than continuous stimulation, which is the main reason it is compared against DAC-conjugated CJC-1295. Published human outcome data on the combination is limited, so most claims about benefits rest on mechanism and small studies rather than large trials.
Should researchers use CJC-1295 with DAC or without DAC?
The choice depends on what the study is measuring. CJC-1295 with DAC binds albumin through its maleimide group, which shields the peptide from enzymatic cleavage and extends its duration of action considerably. CJC-1295 no DAC lacks that extension, so it clears faster and produces a shorter, more pulse-like signal. A study tracking sustained receptor occupancy fits the DAC version; a study tracking pulsatile release kinetics or natural growth hormone pulse patterns fits the no-DAC version. The two are not interchangeable in a protocol, and switching between them changes the baseline you are measuring against.
How is CJC-1295 peptide purity testing actually verified?
Purity is normally established with high-performance liquid chromatography, which separates the target peptide from truncated sequences and synthesis byproducts, and confirmed with mass spectrometry for molecular identity. A certificate of analysis should report both, along with the batch or lot number that matches the vial you received. Ask for the chromatogram itself, not just a percentage, and check that the lot number on the document matches the label. Endotoxin and heavy metal testing are separate assays and are not covered by an HPLC purity figure alone.
What are the known risks and limitations of CJC-1295 and Ipamorelin research?
The main limitation is the evidence base. Much of what circulates about the combination comes from mechanistic work and anecdotal reports rather than large controlled human trials, so benefit claims should be read as hypotheses. On the risk side, growth hormone secretagogues can affect glucose handling and fluid balance, and researchers with existing endocrine or metabolic conditions are generally treated as a higher-risk group in the literature. Neither compound is approved for human use, and this information is educational only. Anyone considering personal use should speak with a qualified physician rather than rely on research summaries.
The hard part of this research is not finding peptides. It is finding documentation you can defend in a lab notebook six months from now. The Peptides King exists for that second problem: every compound ships with HPLC testing, a verified COA tied to its batch, and consistent quality across reorders, backed by support that answers documentation questions directly. Get started with The Peptides King and source research materials you can trace from vial to chromatogram.
